Funding Awarded to Another Eight Interim Applicants

Author:

David Garmaise

Article Type:

Article Number: 2

Tanzania, Nigeria and South Africa receive the largest awards

ABSTRACT Funding in the amount of up to $411.2 million has been approved for eight interim applicants. This brings to 26 the number of interim applicants for which funding has been awarded, out of the 48 invited to apply when the new funding model was launched.

The Board of the Global Fund to Fights AIDS, Tuberculosis and Malaria has approved funding in the amount of up to $411.2 million for eight interim applicants in the transition phase of the new funding model (NFM). Each applicant was awarded funding for just one component. However, in some countries the new funding will be split among multiple grants for the same component. See the table for details.

In approving the funding, the Board was acting on recommendations from the Technical Review Panel (TRP) and the Secretariat, including the Grant Approvals Committee (GAC).

This brings to 26 the number of interim applicants for which funding has been awarded. When the NFM was launched, the Global Fund said that 48 interim applicants had been invited to apply. More approvals are expected in the coming months.

The largest awards went to Tanzania ($114 million for three HIV grants), Nigeria ($121.0 million for three HIV malaria grants) and South Africa ($90.6 million for HIV and TB programming).

Table: Interim Funding Awards from GAC Report GF-B29-ER5

Country	Component	Grant Number	Ceiling ($US million)
Cameroon	HIV	CMR-011-G11-H	$20.4
Cote d’Ivoire	Malaria	CIV-809-G09-M	$57.7
Niger	HIV	NGR-708-G08-H	$1.0
Nigeria	HIV	NGA-H-NACA	$112.9
	HIV	HGA-H-ARFH	$0.2
	HIV	NGA-H-SFHNG	$7.9
Russian Federation	HIV	RUS-304-G01-H	$2.5
South Africa	HIV	SAF-H-RTC	$2.0
	HIV	SAF-910-G09-H	$2.0
	TB	SAF-H-NDOH	$55.0
	HIV	SAF-H-NACOSA	$25.0
	HIV	TBD	$6.6
Tanzania	Malaria	TNZ-M-MOFEA	$114.0
		TNZ-809-G11-M
		TNZ-102-G01-M
Yemen	Malaria	YEM-708-G06-M	$4.0
TOTAL			$411.2

Note: The TB funding of $55 million shown for South Africa will be added to an existing HIV grant (SAF-H-NDOH) even though the money will be used for TB activities.

All of the amounts shown in the table are ceilings; the amounts finally committed could be less.

The breakdown of funding by disease is as follows: HIV $180.5 million (44%%), malaria $175.7 million (43%) and TB $55.0 million (13%).

One of the applicants, South Africa, was also awarded grant renewal funding (see GFO article). GFO will report on some of these comments in the coming weeks.

In its report, the GAC provided comments on the funding awards to individual countries (see separate articles on GFO Live).

Information for this article was taken from Board Decisions GF-B29-EDP8 and GF-B29-EDP9, and from GF-B29-ER5, the Report of Secretariat Funding Recommendations. These documents are not available on the Global Fund website. Additional information was obtained from the Global Fund Secretariat.